Vericel (VCEL) Receives Coverage Optimism Rating of 0.13

News articles about Vericel (NASDAQ:VCEL) have trended somewhat positive on Saturday, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vericel earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.5932107894481 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Vericel (NASDAQ:VCEL) traded up $0.17 on Friday, reaching $6.63. 607,044 shares of the company traded hands, compared to its average volume of 648,244. The company has a market cap of $225.15, a P/E ratio of -7.53 and a beta of 3.02. Vericel has a 52 week low of $2.25 and a 52 week high of $6.75. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.22 and a current ratio of 2.50.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The company had revenue of $14.26 million during the quarter. Vericel had a negative net margin of 45.11% and a negative return on equity of 265.45%. equities analysts anticipate that Vericel will post -0.6 earnings per share for the current year.

Several equities research analysts have recently issued reports on VCEL shares. BTIG Research set a $6.00 price target on shares of Vericel and gave the stock a “buy” rating in a research note on Monday, October 2nd. ValuEngine lowered shares of Vericel from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $9.00 price objective on shares of Vericel in a report on Tuesday, January 2nd.

ILLEGAL ACTIVITY WARNING: “Vericel (VCEL) Receives Coverage Optimism Rating of 0.13” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.themarketsdaily.com/2018/01/13/vericel-vcel-receives-coverage-optimism-rating-of-0-13.html.

Vericel Company Profile

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Insider Buying and Selling by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply